{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:02:56Z","timestamp":1767873776036,"version":"3.49.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T00:00:00Z","timestamp":1722902400000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s40266-024-01136-7","type":"journal-article","created":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T12:03:07Z","timestamp":1722945787000},"page":"685-697","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-World Drug Survival of Biologics and Targeted Synthetic Disease-Modifying Anti-rheumatic Drugs Among Patients with Psoriatic Arthritis"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1535-7091","authenticated-orcid":false,"given":"Vered","family":"Rosenberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howard","family":"Amital","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Chodick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Freddy","family":"Faccin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Gendelman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,6]]},"reference":[{"key":"1136_CR1","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","volume":"41","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41:545\u201368.","journal-title":"Rheum Dis Clin North Am"},{"key":"1136_CR2","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/rheumatology\/kex323","volume":"56","author":"W Tillett","year":"2017","unstructured":"Tillett W, Charlton R, Nightingale A, Snowball J, Green A, Smith C, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatology (Oxford). 2017;56:2109\u201313.","journal-title":"Rheumatology (Oxford)"},{"key":"1136_CR3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s13075-017-1497-4","volume":"20","author":"L Eder","year":"2018","unstructured":"Eder L, Cohen AD, Feldhamer I, Greenberg-Dotan S, Batat E, Zisman D. The epidemiology of psoriatic arthritis in Israel\u2014a population-based study. Arthritis Res Ther. 2018;20:3.","journal-title":"Arthritis Res Ther"},{"key":"1136_CR4","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1136\/annrheumdis-2013-204858","volume":"74","author":"M Haroon","year":"2015","unstructured":"Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045\u201350.","journal-title":"Ann Rheum Dis"},{"key":"1136_CR5","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","volume":"14","author":"T Gudu","year":"2018","unstructured":"Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14:405\u201317.","journal-title":"Expert Rev Clin Immunol"},{"key":"1136_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/OARRR.S56073","volume":"9","author":"S D\u2019Angelo","year":"2017","unstructured":"D\u2019Angelo S, Tramontano G, Gilio M, Leccese P, Olivieri I. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017;9:21\u20138.","journal-title":"Open Access Rheumatol"},{"key":"1136_CR7","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21:1690.","journal-title":"Int J Mol Sci"},{"key":"1136_CR8","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3899\/jrheum.170098","volume":"44","author":"D Ben-Ami Shor","year":"2017","unstructured":"Ben-Ami Shor D, Weitzman D, Dahan S, Gendelman O, Bar-On Y, Amital D, et al. Adherence and persistence with drug therapy among fibromyalgia patients: data from a large health maintenance organization. J Rheumatol. 2017;44:1499\u2013506.","journal-title":"J Rheumatol"},{"key":"1136_CR9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-001117","volume":"6","author":"A Ruyssen-Witrand","year":"2020","unstructured":"Ruyssen-Witrand A, Perry R, Watkins C, Braileanu G, Kumar G, Kiri S, et al. Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020;6: e001117.","journal-title":"RMD Open"},{"key":"1136_CR10","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1111\/jdv.15482","volume":"33","author":"C Dressler","year":"2019","unstructured":"Dressler C, Eisert L, Pham PA, Nast A. Efficacy and safety of systemic treatments in psoriatic arthritis: a systematic review, meta-analysis and GRADE evaluation. J Eur Acad Dermatol Venereol. 2019;33:1249\u201360.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1136_CR11","volume":"8","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Sawyer LM, Markus K, LeReun C, Sabry-Grant C, Helliwell PS. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes. RMD Open. 2022;8: e002074.","journal-title":"RMD Open"},{"key":"1136_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","volume":"47","author":"JF Merola","year":"2017","unstructured":"Merola JF, Lockshin B, Mody EA. Switching biologics in the treatment of psoriatic arthritis. Semin Arthritis Rheum. 2017;47:29\u201337.","journal-title":"Semin Arthritis Rheum"},{"key":"1136_CR13","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1007\/s10067-016-3204-2","volume":"35","author":"P Ungprasert","year":"2016","unstructured":"Ungprasert P, Thongprayoon C, Davis JM. Indirect comparisons of the efficacy of subsequent biological agents in patients with psoriatic arthritis with an inadequate response to tumor necrosis factor inhibitors: a meta-analysis. Clin Rheumatol. 2016;35:1795\u2013803.","journal-title":"Clin Rheumatol"},{"key":"1136_CR14","first-page":"700","volume":"79","author":"L Gossec","year":"2020","unstructured":"Gossec L, Baraliakos X, Kerschbaumer A, de Wit M, McInnes I, Dougados M, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79:700\u201312.","journal-title":"Ann Rheum Dis"},{"key":"1136_CR15","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1524-4733.2007.00213.x","volume":"11","author":"JA Cramer","year":"2008","unstructured":"Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44\u20137.","journal-title":"Value Health."},{"key":"1136_CR16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/jdv.13611","volume":"30","author":"A Menter","year":"2016","unstructured":"Menter A, Papp KA, Gooderham M, Pariser DM, Augustin M, Kerdel FA, et al. Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). J Eur Acad Dermatol Venereol. 2016;30:1148\u201358.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1136_CR17","doi-asserted-by":"crossref","first-page":"16068","DOI":"10.1038\/s41598-018-34293-y","volume":"8","author":"P-T Lin","year":"2018","unstructured":"Lin P-T, Wang S-H, Chi C-C. Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence. Sci Rep. 2018;8:16068.","journal-title":"Sci Rep"},{"key":"1136_CR18","volume":"5","author":"JS Smolen","year":"2019","unstructured":"Smolen JS, Gladman D, McNeil HP, Mease PJ, Sieper J, Hojnik M, et al. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study. RMD Open. 2019;5: e000585.","journal-title":"RMD Open"},{"key":"1136_CR19","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.semarthrit.2016.09.005","volume":"46","author":"K Aaltonen","year":"2017","unstructured":"Aaltonen K, Heinonen A, Joensuu J, Parmanne P, Karjalainen A, Varjolahti-Lehtinen T, et al. Effectiveness and drug survival of TNF-inhibitors in the treatment of psoriatic arthritis: a prospective cohort study. Semin Arthritis Rheum. 2017;46:732\u20139.","journal-title":"Semin Arthritis Rheum"},{"key":"1136_CR20","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.18549\/PharmPract.2021.2.2312","volume":"19","author":"AF Souza","year":"2021","unstructured":"Souza AF, da Silva MR, dos Santos JB, Almeida AM, Acurcio FA, Alvares-Teodoro J. Medication adherence and persistence of psoriatic arthritis patients treated with biological therapy in a specialty pharmacy in Brazil: a prospective observational study. Pharm Pract (Granada). 2021;19:2312\u20132312.","journal-title":"Pharm Pract (Granada)."},{"key":"1136_CR21","doi-asserted-by":"crossref","first-page":"607","DOI":"10.2217\/cer-2019-0023","volume":"8","author":"KR Oelke","year":"2019","unstructured":"Oelke KR, Chambenoit O, Majjhoo AQ, Gray S, Higgins K, Hur P. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Eff Res. 2019;8:607\u201321.","journal-title":"J Comp Eff Res."},{"key":"1136_CR22","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D, L\u00f8rup EH, Nielsen M-L, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis\u2014a nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53: 151979.","journal-title":"Semin Arthritis Rheum"},{"key":"1136_CR23","doi-asserted-by":"crossref","first-page":"206","DOI":"10.18553\/jmcp.2022.28.2.206","volume":"28","author":"MJ Murage","year":"2022","unstructured":"Murage MJ, Princic N, Park J, Malatestinic WN, Zhu B, Atiya B, et al. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. JMCP. 2022;28:206\u201317.","journal-title":"JMCP."},{"key":"1136_CR24","unstructured":"The Research and Planning Administration, The National Insurance Institute, Israel, Healthfunds Membership 2018\u20132019. Retrieved July 12, 2024, from https:\/\/www.btl.gov.il\/Publications\/survey\/Documents\/seker317\/seker_317.pdf"},{"key":"1136_CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3121\/cmr.8.1.38-b","volume":"8","author":"V Shalev","year":"2010","unstructured":"Shalev V, Chodick G, Goren I, Silber H, Kokia E, Heymann AD. PS2-18: the Maccabi Healthcare Services cardiovascular information system: integration of patient care data, registries, and guide. Clin Med Res. 2010;8:38.","journal-title":"Clin Med Res"},{"key":"1136_CR26","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.3094","volume":"35","author":"A Cahn","year":"2019","unstructured":"Cahn A, Altaras T, Agami T, Liran O, Touaty CE, Drahy M, et al. Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database. Diabetes Metab Res Rev. 2019;35: e3094.","journal-title":"Diabetes Metab Res Rev"},{"issue":"Suppl 1","key":"1136_CR27","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1097\/01.hjh.0001021016.77442.bb","volume":"42","author":"A Leiba","year":"2024","unstructured":"Leiba A, Lencovsky O, Azran C, Hadad O, Rappoprt V, Niddam NN, et al. True refractory hypertension in 2023\u2014lessons learned from a national registry of 1.82 million adults. J Hypertens. 2024;42(Suppl 1):e163.","journal-title":"J Hypertens"},{"key":"1136_CR28","doi-asserted-by":"crossref","first-page":"A389","DOI":"10.1016\/j.jval.2014.08.2665","volume":"17","author":"I Goldshtein","year":"2014","unstructured":"Goldshtein I, Shalev V, Chodick G, Chandler J, Martin NA, Ish SS. The use of clinical data repository for the establishment of an osteoporosis registry in a large health organization in Israel: epidemiologic and pharmaepidemiologic findings. Value Health. 2014;17:A389-390.","journal-title":"Value Health."},{"key":"1136_CR29","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3899\/jrheum.210349","volume":"49","author":"GE Fragoulis","year":"2022","unstructured":"Fragoulis GE, Nikiphorou E, McInnes IB, Siebert S. Does age matter in psoriatic arthritis? A narrative review. J Rheumatol. 2022;49:1085\u201391.","journal-title":"J Rheumatol"},{"key":"1136_CR30","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/ard.58.4.226","volume":"58","author":"L Punzi","year":"1999","unstructured":"Punzi L, Pianon M, Rossini P, Schiavon F, Gambari PF. Clinical and laboratory manifestations of elderly onset psoriatic arthritis: a comparison with younger onset disease. Ann Rheum Dis. 1999;58:226\u20139.","journal-title":"Ann Rheum Dis"},{"key":"1136_CR31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s13075-021-02417-x","volume":"23","author":"A Haddad","year":"2021","unstructured":"Haddad A, Gazitt T, Feldhamer I, Feld J, Cohen AD, Lavi I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021;23:44.","journal-title":"Arthritis Res Ther"},{"key":"1136_CR32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1080\/03007995.2020.1754186","volume":"36","author":"JA Walsh","year":"2020","unstructured":"Walsh JA, Cai Q, Lin I, Fitzgerald T, Pericone CD, Chakravarty SD. Real-world 2-year treatment patterns among patients with psoriatic arthritis treated with injectable biologic therapies. Curr Med Res Opin. 2020;36:1245\u201352.","journal-title":"Curr Med Res Opin"},{"key":"1136_CR33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamadermatol.2022.0364","volume":"158","author":"L Pina Vegas","year":"2022","unstructured":"Pina Vegas L, Penso L, Claudepierre P, Sbidian E. Long-term persistence of first-line biologics for patients with psoriasis and psoriatic arthritis in the French Health Insurance Database. JAMA Dermatol. 2022;158:513\u201322.","journal-title":"JAMA Dermatol"},{"key":"1136_CR34","volume":"8","author":"LP Vegas","year":"2022","unstructured":"Vegas LP, Hoisnard L, Bastard L, Sbidian E, Claudepierre P. Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD Open. 2022;8: e002681.","journal-title":"RMD Open"},{"key":"1136_CR35","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","volume":"43","author":"LE Kristensen","year":"2016","unstructured":"Kristensen LE, Lie E, Jacobsson LTH, Christensen R, Mease PJ, Bliddal H, et al. Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern Sweden. J Rheumatol. 2016;43:81\u20137.","journal-title":"J Rheumatol"},{"key":"1136_CR36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/1759720X16673786","volume":"9","author":"M Reed","year":"2017","unstructured":"Reed M, Crosbie D. Apremilast in the treatment of psoriatic arthritis: a perspective review. Ther Adv Musculoskeletal. 2017;9:45\u201353.","journal-title":"Ther Adv Musculoskeletal."},{"key":"1136_CR37","doi-asserted-by":"crossref","first-page":"693","DOI":"10.3899\/jrheum.191209","volume":"48","author":"A Ogdie","year":"2021","unstructured":"Ogdie A, Liu M, Glynn M, Emeanuru K, Harrold LR, Richter S, et al. Descriptive comparisons of the effect of apremilast and methotrexate monotherapy in oligoarticular psoriatic arthritis: the corrona psoriatic arthritis\/spondyloarthritis registry results. J Rheumatol. 2021;48:693\u20137.","journal-title":"J Rheumatol"},{"key":"1136_CR38","doi-asserted-by":"crossref","first-page":"699","DOI":"10.2217\/cer-2019-0034","volume":"8","author":"SR Feldman","year":"2019","unstructured":"Feldman SR, Pelletier CL, Wilson KL, Mehta RK, Brouillette MA, Smith D, et al. Treatment patterns and costs among biologic-naive patients initiating apremilast or biologics for psoriatic arthritis. J Comp Eff Res. 2019;8:699\u2013709.","journal-title":"J Comp Eff Res."},{"key":"1136_CR39","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40744-021-00397-7","volume":"9","author":"S Patel","year":"2022","unstructured":"Patel S, Kumthekar A. Psoriatic arthritis: the influence of co-morbidities on drug choice. Rheumatol Ther. 2022;9:49\u201371.","journal-title":"Rheumatol Ther."},{"key":"1136_CR40","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1136\/annrheumdis-2017-211284","volume":"76","author":"B Michelsen","year":"2017","unstructured":"Michelsen B, Kristianslund EK, Sexton J, Hammer HB, Fagerli KM, Lie E, et al. Do depression and anxiety reduce the likelihood of remission in rheumatoid arthritis and psoriatic arthritis? Data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76:1906\u201310.","journal-title":"Ann Rheum Dis"},{"key":"1136_CR41","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/jdv.13306","volume":"30","author":"N Betteridge","year":"2016","unstructured":"Betteridge N, Boehncke W-H, Bundy C, Gossec L, Gratac\u00f3s J, Augustin M. Promoting patient-centred care in psoriatic arthritis: a multidisciplinary European perspective on improving the patient experience. J Eur Acad Dermatol Venereol. 2016;30:576\u201385.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1136_CR42","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","volume":"7","author":"A Kumthekar","year":"2020","unstructured":"Kumthekar A, Ogdie A. Obesity and psoriatic arthritis: a narrative review. Rheumatol Ther. 2020;7:447\u201356.","journal-title":"Rheumatol Ther."},{"key":"1136_CR43","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001975","volume":"7","author":"M Deike","year":"2021","unstructured":"Deike M, Brinks R, Meller S, Schneider M, Sewerin P. Risk of psoriatic arthritis depending on age: analysis of data from 65 million people on statutory insurance in Germany. RMD Open. 2021;7: e001975.","journal-title":"RMD Open"},{"key":"1136_CR44","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40266-019-00688-3","volume":"36","author":"F Caso","year":"2019","unstructured":"Caso F, Tasso M, Chimenti MS, Navarini L, Perricone C, Girolimetto N, et al. Late-onset and elderly psoriatic arthritis: clinical aspects and management. Drugs Aging. 2019;36:909\u201325.","journal-title":"Drugs Aging"},{"key":"1136_CR45","first-page":"792","volume":"13","author":"CG Gialouri","year":"2023","unstructured":"Gialouri CG, Evangelatos G, Iliopoulos A, Tektonidou MG, Sfikakis PP, Fragoulis GE, et al. Late-onset psoriatic arthritis: are there any distinct characteristics? A Retrospective cohort data analysis. Life (Basel). 2023;13:792.","journal-title":"Life (Basel)."},{"issue":"Suppl 1","key":"1136_CR46","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/annrheumdis-2022-eular.2721","volume":"81","author":"E G\u00f6n\u00fcll\u00fc","year":"2022","unstructured":"G\u00f6n\u00fcll\u00fc E, Kalyoncu U, Ya\u011fiz B, Ate\u015f A, K\u00fc\u00e7\u00fck\u015fahin O, Ya\u015far Bilge \u015e, et al. AB0355 the differences between the first preferred biological DMARD and the drug survival in geriatric and younger adult population with rheumatoid arthritis and psoriatic arthritis: treasure real-life data. Ann Rheum Dis. 2022;81(Suppl 1):1304.","journal-title":"Ann Rheum Dis"},{"key":"1136_CR47","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10067-018-3989-2","volume":"37","author":"F Iannone","year":"2018","unstructured":"Iannone F, Santo L, Bucci R, Semeraro A, Carlino G, Paoletti F, et al. Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE). Clin Rheumatol. 2018;37:667\u201375.","journal-title":"Clin Rheumatol"},{"issue":"Suppl 2","key":"1136_CR48","first-page":"1847","volume":"78","author":"J-G Letarouilly","year":"2019","unstructured":"Letarouilly J-G, Sellam J, Richette P, Dieud\u00e9 P, Claudepierre P, Richard CM, et al. Ab0760 Drug survival and efficacy of ustekinumab and secukinumab in psoriatic arthritis: a real-world multicentric cohort of 186 patients. Ann Rheum Dis. 2019;78(Suppl 2):1847\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1136_CR49","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s12325-021-01687-w","volume":"38","author":"JA Walsh","year":"2021","unstructured":"Walsh JA, Cai Q, Lin I, Pericone CD, Chakravarty SD. Treatment persistence and adherence among patients with psoriatic arthritis who initiated targeted immune modulators in the US: a retrospective cohort study. Adv Ther. 2021;38:2353\u201364.","journal-title":"Adv Ther"},{"key":"1136_CR50","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/ds.ds_8_22","volume":"40","author":"S Yu","year":"2022","unstructured":"Yu S, Tsao Y-H, Tu H-P, Lan C-CE. Drug survival of biologic agents in patients with psoriatic arthritis from a medical center in southern Taiwan. Dermatol Sin. 2022;40:20.","journal-title":"Dermatol Sin"},{"key":"1136_CR51","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.clinthera.2013.07.328","volume":"35","author":"B Zhu","year":"2013","unstructured":"Zhu B, Edson-Heredia E, Gatz JL, Guo J, Shuler CL. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study. Clin Ther. 2013;35:1376\u201385.","journal-title":"Clin Ther"},{"key":"1136_CR52","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1186\/s13075-014-0420-5","volume":"16","author":"HF Zhang","year":"2014","unstructured":"Zhang HF, Gauthier G, Hiscock R, Curtis JR. Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2014;16:420.","journal-title":"Arthritis Res Ther"},{"key":"1136_CR53","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/ard-2022-223650","volume":"82","author":"B Glintborg","year":"2023","unstructured":"Glintborg B, Di Giuseppe D, Wallman JK, Nordstr\u00f6m DC, Gudbjornsson B, Hetland ML, et al. Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Ann Rheum Dis. 2023;82:820\u20138.","journal-title":"Ann Rheum Dis"}],"container-title":["Drugs &amp; Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40266-024-01136-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-024-01136-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T14:07:46Z","timestamp":1732543666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40266-024-01136-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":53,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1007\/s40266-024-01136-7","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"14 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by Tel Aviv University. AbbVie Inc. (North Chicago, Illinois, USA) funded the research. AbbVie and Maccabi participated in the study design, research, analysis, data collection, interpretation of the data, review and approval of the manuscript and publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"F. Faccin is a full-time AbbVie employee and may own AbbVie stock and\/or options. V. Rosenberg, G. Chodick, and G.O. Gendelman declare that they have no conflict of interest. H. Amital received consultant fees from AbbVie for this project. After completion of the manuscript, G. Chodick changed his affiliation within Maccabi Healthcare Services, and his new affiliation is: Maccabi Healthcare Services, Tel Aviv, Israel. His other affiliation, of Tel Aviv university, remains the same.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the protocol, applicable regulations, and guidelines governing clinical study conduct and the ethical principles that have their origin in the Declaration of Helsinki. The independent ethics committee and institutional review board, MHS Institutional Review Board, approved the study protocol and related documents (approval number 0108-18-BBL, 18 December 2018). MHS\u2019s IRB waived the requirement to obtain any informed consent for this secondary analysis of existing data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval consent to participate"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work, and have given their approval for this version to be published. No honoraria or payments were made for authorship.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during and\/or analyzed during the current study are not publicly available because the data that support the findings of this study originate from Maccabi Healthcare Services and restrictions apply to the availability of these data. Due to restrictions, these data can be accessed only by request to the authors and\/or Maccabi Healthcare Services.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and materials"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by V. Rosenberg and Drs. Amital, Chodick, and Gendelman. The first draft of the manuscript was written by V. Rosenberg and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contribution"}}]}}